Several studies have assessed the therapeutic potential of the fusion protein L19-IL2, which consists of an interleukin 2 (IL2) coupled to a monoclonal antibody directed against FN1. Promising experimental and clinical results have been reported in case of metastatic melanoma [65] and renal cell carcinoma [70]. This evidence concerns the gene FN1 and renal cell carcinoma.